TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression

Neoplasia

Volumn 12, Issue 5, 2010, Pages 405-414

  Lafferty Whyte, Kyle ^a   Bilsland, Alan ^a   Hoare, Stacey F ^a   Burns, Sharon ^a   Zaffaroni, Nadia ^b   Cairney, Claire J ^a   Keith, William Nicol ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAD PROTEIN; MAX PROTEIN; MYC PROTEIN; SMALL INTERFERING RNA; TCEAL7 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TELOMERE; TRANSCRIPTION REGULATION;

EID: 77951691483     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10180     Document Type: Article

References (31)

1. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, et al. (2008). A prostatic intraepithelial neoplasiadependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146-155.
2. Feldser DM and Greider CW (2007). Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461-469.
3. Prieur A and Peeper DS (2008). Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 20, 150-155.
4. Bilsland AE, Fletcher-Monaghan A, and Keith WN (2005). Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia 7, 1020-1029.
5. Perez JM, Grimm J, Josephson L, and Weissleder R (2008). Integrated nanosensors to determine levels and functional activity of human telomerase. Neoplasia 10, 1066-1072.
6. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, et al. (2005). A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 11, 217-225.
7. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, and Ladanyi M (2004). Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41, 155-162.
8. Royle NJ, Mendez-Bermudez A, Gravani A, Novo C, Foxon J, Williams J, Cotton V, and Hidalgo A (2009). The role of recombination in telomere length maintenance. Biochem Soc Trans 37, 589-595.
9. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, and Keith WN (2008). High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 98, 1467-1474.
10. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, et al. (2006). Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 66, 8918-8924.
11. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, and Royds JA (2003). Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361, 836-838.
12. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, et al. (2003). Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63, 1759-1763.
13. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A, et al. (2008). Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res 14, 4134-4140.
14. Bilsland AE, Hoare S, Stevenson K, Plumb J, Gomez-Roman N, Cairney C, Burns S, Lafferty-Whyte K, Roffey J, Hammonds T, et al. (2009). Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS One 4, e6459.
15. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, Zaffaroni N, Bilsland A, and Keith WN (2009). A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 28(43), 3765-3774.
16. Atkinson SP, Hoare SF, Glasspool RM, and Keith WN (2005). Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65, 7585-7590.
17. Lu X, Pearson A, and Lunec J (2003). The MYCN oncoprotein as a drug development target. Cancer Lett 197, 125-130.
18. Meyer N and Penn LZ (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8, 976-990.
19. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV, and Nikiforov MA (2008). c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27, 1905-1915.
20. Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, Wawrzyniak JA, Berman AE, Giordano TJ, Prochownik EV, Soengas MS, et al. (2008). C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27, 6623-6634.
21. Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, and Felsher DW (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 104, 13028-13033.
22. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, and Dang CV (2003). An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4(10), R69.
23. Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, et al. (2008). A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene 27, 7223-7234.
24. Herold S, Herkert B, and Eilers M (2009). Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer 9, 441-444.
25. D-O, Kim M-O, Lee J-D, Choi YH, and Kim G-Y (in press). Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett 286(2), 172-179.
26. Bazarov AV, Hines WC, Mukhopadhyay R, Beliveau A, Melodyev S, Zaslavsky Y, and Yaswen P (2009). Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes. Cell Cycle 8(20), 3373-3378.
27. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, and Land H (1993). Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72,233-245.
28. Ayer DE, Kretzner L, and Eisenman RN (1993). Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72, 211-222.
29. Ge Z, Li W, Wang N, Liu C, Zhu Q, Bjorkholm M, Gruber A, and Xu D (2010). Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J 24(2), 579-586.
30. Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, Kaufmann SH, Smith DI, and Shridhar V (2005). Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24, 5089-5100.
31. Peedicayil A, Vierkant RA, Shridhar V, Schildkraut JM, Armasu S, Hartmann LC, Fridley BL, Cunningham JM, Phelan CM, Sellers TA, et al. (2009). Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. Gynecol Oncol 114, 260-264.